MRP51 Antibody

What are the validated applications for MRPL51 antibodies?

MRPL51 antibodies have been validated for multiple experimental applications including Western blotting (WB), immunohistochemistry on paraffin-embedded tissues (IHC-P), and enzyme-linked immunosorbent assay (ELISA). Based on experimental validation, the Rabbit Polyclonal MRPL51 antibody (ab235828) has been confirmed suitable for WB at 1/1000 dilution and IHC-P at 1/100 dilution with human samples . Similarly, the MRPL51 Polyclonal Antibody (CAC14204) has been validated for ELISA, WB, and IHC applications with human samples . When designing experiments, researchers should consider that these antibodies have been tested primarily with human samples, and cross-reactivity with other species may require additional validation.

What is the recommended protocol for Western blotting with MRPL51 antibodies?

For Western blotting with MRPL51 antibodies, researchers should prepare whole cell lysates (as demonstrated with K562 human chronic myelogenous leukemia cell line) and use the antibody at a 1/1000 dilution . The predicted band size for MRPL51 is approximately 15 kDa. For detection, a secondary antibody such as Goat polyclonal to rabbit IgG at 1/10000 dilution is recommended . It's important to include appropriate controls and optimize conditions based on your specific experimental setup. Note that cell lysis methods, protein load, and exposure times may need adjustment depending on cell types and expression levels of the target protein.

What are the primary applications for MRP1 antibodies in research?

MRP1 antibodies have been validated for Western blotting (WB), immunocytochemistry/immunofluorescence (ICC/IF), and immunohistochemistry on paraffin-embedded tissues (IHC-P) . The Rabbit Recombinant Monoclonal MRP1 antibody [EPR21062] (ab233383) has been cited in 22 publications, demonstrating its reliability for research applications . MRP1 antibodies are particularly useful in cancer research, as MRP1 mediates drug resistance by exporting chemotherapeutic agents from cells. When selecting an MRP1 antibody, researchers should consider whether they need species cross-reactivity, as some antibodies like MRP1-A23 can detect MRP1 in both human and rodent tissues .

How do I optimize immunohistochemistry protocols for MRPL51 detection?

For optimal immunohistochemical detection of MRPL51, use paraffin-embedded tissue sections and the antibody at a 1/100 dilution . Based on experimental validation with human small intestine tissue, this concentration provides good signal-to-noise ratio. The staining protocol should include appropriate antigen retrieval methods, blocking steps to minimize non-specific binding, and incubation with a suitable detection system. While specific heat-mediated antigen retrieval buffers aren't specified for MRPL51 antibodies in the search results, researchers might consider adopting similar protocols to those used for MRP1 detection, which recommends using Tris-EDTA Buffer (pH 9.0) . Always include positive and negative controls to validate staining specificity.

How can I distinguish between true MRPL51 signal and cross-reactivity in my experiments?

To distinguish between true MRPL51 signal and potential cross-reactivity, implement multiple validation strategies. First, compare your experimental results with the predicted molecular weight of MRPL51 (15 kDa) . Second, include knockout or knockdown controls where MRPL51 expression is eliminated or reduced. Third, use multiple antibodies targeting different epitopes of MRPL51 to confirm consistent patterns. Fourth, perform peptide competition assays using the immunogen peptide to confirm binding specificity. Additionally, consider cross-validating your findings with complementary techniques such as mass spectrometry or RNA expression analysis. Remember that antibody specificity can be affected by experimental conditions, fixation methods, and the presence of closely related proteins.

What are the critical considerations when comparing MRP1 expression in normal versus cancerous tissues?

When comparing MRP1 expression between normal and cancerous tissues, several methodological considerations are crucial. Based on immunohistochemical analyses, MRP1 typically shows strong membranous and cytoplasmic staining in cancer tissues (such as gastric and lung cancer) with weak staining in adjacent non-cancerous tissues . To ensure reliable comparisons, researchers should: (1) Use consistent antibody concentrations (e.g., 1/4000 dilution for IHC-P with ab233383); (2) Perform heat-mediated antigen retrieval using standardized buffers (Tris-EDTA buffer, pH 9.0 recommended); (3) Include both tissues on the same slide when possible to minimize technical variations; (4) Use appropriate secondary antibody controls; (5) Quantify staining intensity using digital image analysis rather than subjective assessments; (6) Consider the heterogeneity of cancer tissues by examining multiple regions; and (7) Correlate protein expression with functional assays or clinical data for meaningful interpretations.

How does species cross-reactivity affect antibody selection for comparative studies between human and rodent models?

Species cross-reactivity is a critical factor when selecting antibodies for comparative studies between human and rodent models. Most commercially available MRPL51 antibodies have been primarily validated for human samples , which may limit their utility in rodent studies without additional validation. In contrast, for MRP1 research, specifically designed antibodies like MRP1-A23 recognize human, mouse, and rat MRP1 due to the high sequence identity in the C-terminus region . This antibody shows similar reactivity to human MRP1 as the monoclonal QCRL1 antibody but with the added advantage of rodent cross-reactivity . When planning comparative studies, researchers should:

• Examine sequence homology between species for the target protein

• Consult validation data for each species of interest

• Perform preliminary testing in both species before large-scale experiments

• Consider developing custom antibodies for highly divergent regions

• Be aware that cross-reactivity might introduce unexpected binding to homologous proteins (e.g., MRP1-A23 weakly cross-reacts with rat MRP2 in the 1512-1533 amino acid region)

What methodological approaches can resolve discrepancies in MRP1 detection between different experimental techniques?

When facing discrepancies in MRP1 detection between different experimental techniques, a systematic troubleshooting approach is necessary. First, verify antibody specificity using knockout controls, as demonstrated with ABCC1 knockout HeLa cells where MRP1 antibody signal was lost compared to wild-type cells . Second, optimize protein extraction methods, as membrane proteins like MRP1 may require specific detergents or extraction protocols. Third, consider post-translational modifications that might affect epitope recognition across different techniques. Fourth, examine subcellular localization—MRP1 shows both membranous and cytoplasmic staining patterns , which might appear different depending on the technique used. Fifth, quantify expression using multiple methods (e.g., Western blot, qPCR, immunostaining) to triangulate actual expression levels. Finally, standardize sample preparation protocols across techniques to minimize variation from fixation, antigen retrieval, or protein denaturation.

How should researchers design antibody validation experiments for MRPL51 in novel cell types or tissues?

When validating MRPL51 antibodies in novel cell types or tissues, implement a comprehensive validation strategy. Begin with bioinformatic analysis to confirm MRPL51 expression in your target tissue using public databases. Then perform Western blotting to verify the antibody detects a band at the expected molecular weight (15 kDa) . Include positive controls (e.g., K562 cells) where the antibody has been previously validated . For tissues, compare your staining patterns with known MRPL51 expression in repositories like the Human Protein Atlas. Consider using siRNA or CRISPR knockout controls to confirm specificity. For novel applications beyond WB and IHC-P, perform titration experiments to determine optimal antibody concentrations. Finally, validate findings with orthogonal methods such as RNA analysis or mass spectrometry. Document all validation steps methodically to establish the reliability of your antibody for the specific experimental context.

What are the optimal fixation and antigen retrieval methods for detecting MRP1 in tissue samples?

For optimal detection of MRP1 in tissue samples, formalin fixation followed by paraffin embedding has been successfully employed . The critical step is the antigen retrieval process, where heat-mediated antigen retrieval using Tris-EDTA Buffer (pH 9.0) is specifically recommended for MRP1 detection . This approach has been validated for detecting membranous and cytoplasmic MRP1 in various tissues including gastric and lung cancer samples. The optimal antibody dilution for IHC-P with the Rabbit Recombinant Monoclonal MRP1 antibody [EPR21062] is 1/4000 . Alternative fixation methods (e.g., acetone, methanol) might preserve certain epitopes better but should be validated empirically. For double immunostaining experiments, sequential rather than simultaneous antibody incubation may reduce cross-reactivity. Always include appropriate controls, including secondary antibody-only controls and comparative staining of tissues with known MRP1 expression levels.

How can researchers quantitatively assess MRPL51 expression changes in mitochondrial dysfunction models?

Quantitative assessment of MRPL51 expression changes in mitochondrial dysfunction models requires multiple complementary approaches. For protein-level quantification, Western blotting using MRPL51-specific antibodies at 1/1000 dilution with appropriate housekeeping controls is recommended . Densitometry analysis should be performed across multiple biological replicates (n≥3). For single-cell or tissue-level analysis, quantitative immunofluorescence with standard curves using recombinant MRPL51 protein can provide absolute quantification. RNA-level changes should be measured using qRT-PCR with validated primers spanning exon-exon junctions. Given MRPL51's mitochondrial localization, consider measuring both total cellular levels and mitochondrial fraction levels using appropriate fractionation techniques. Correlate expression changes with functional mitochondrial parameters such as oxygen consumption rate, membrane potential, or translation efficiency of mitochondrial-encoded proteins to establish biological significance.

What controls should be included when investigating MRP1-mediated drug resistance using antibody-based techniques?

When investigating MRP1-mediated drug resistance using antibody-based techniques, comprehensive controls are essential for result interpretation. Include:

• Positive controls: Cell lines with confirmed high MRP1 expression (e.g., drug-resistant cancer cell lines)

• Negative controls: MRP1 knockout cells, as demonstrated with ABCC1 knockout HeLa cells

• Antibody controls: Secondary antibody-only controls to assess non-specific binding

• Expression controls: Gradients of MRP1 expression through inducible systems or dose-dependent drug selection

• Functional controls: Correlate MRP1 protein levels with functional assays (e.g., drug efflux, cytotoxicity assays)

• Specificity controls: Test for cross-reactivity with related transporters (e.g., MRP2), particularly important when using antibodies like MRP1-A23 which shows weak cross-reactivity with rat MRP2

• Treatment controls: Include MRP1 inhibitors to confirm the role of MRP1 in observed resistance

• Loading controls: Use established housekeeping proteins appropriate for the subcellular fraction being analyzed

What are common pitfalls in detecting MRPL51 in different subcellular fractions, and how can they be addressed?

Detecting MRPL51 in subcellular fractions presents several challenges due to its mitochondrial localization. Common pitfalls include:

• Cross-contamination between fractions: Ensure clean separation of mitochondrial fractions using validated protocols and verify with compartment-specific markers (e.g., VDAC for mitochondria, Histone H3 for nucleus).

• Low abundance: MRPL51 is relatively low-abundance compared to cytosolic proteins, requiring sensitive detection methods. Consider using enhanced chemiluminescence or fluorescent secondary antibodies with longer exposure times for Western blots .

• Extraction efficiency: Mitochondrial proteins may require specialized lysis buffers. Standard RIPA buffers may not efficiently extract all mitochondrial proteins. Test alternative extraction methods (e.g., Triton X-100, digitonin-based extraction).

• Size verification: Always confirm the band size matches the predicted 15 kDa for MRPL51 .

• Antibody penetration: For immunofluorescence studies, ensure sufficient permeabilization of mitochondrial membranes without disrupting morphology.

• Signal specificity: Use mitochondrial co-localization markers to confirm MRPL51 signals in the expected subcellular location.

• Fixation artifacts: Overfixation can mask epitopes in mitochondria. Test different fixation times or consider post-fixation antigen retrieval.

How can researchers effectively use MRP1 antibodies to study the relationship between MRP1 expression and clinical drug resistance?

To effectively study the relationship between MRP1 expression and clinical drug resistance, researchers should implement a multi-faceted approach:

What are the key considerations when developing co-immunoprecipitation protocols to study MRPL51 interactions with other mitochondrial ribosomal proteins?

Developing effective co-immunoprecipitation (co-IP) protocols for MRPL51 interactions requires careful consideration of several factors:

• Antibody suitability: Not all antibodies work effectively for co-IP. Test whether MRPL51 antibodies like ab235828 or CAC14204 can efficiently immunoprecipitate native MRPL51.

• Lysis conditions: Mitochondrial ribosomal complexes are sensitive to detergent conditions. Use mild non-ionic detergents (e.g., 0.5-1% NP-40 or Digitonin) to preserve protein-protein interactions.

• Salt concentration: Optimize salt concentrations (typically 100-150mM NaCl) to maintain specific interactions while reducing background.

• Crosslinking consideration: For transient interactions, consider reversible crosslinking with formaldehyde or DSP before lysis.

• Negative controls: Include isotype control antibodies and/or MRPL51-depleted samples to identify non-specific binding.

• Mitochondrial isolation: For cleaner results, consider isolating mitochondria before lysis to enrich for relevant interactions.

• RNase treatment: Test protocols with and without RNase to distinguish RNA-dependent interactions, as mitochondrial ribosomes contain structural RNAs.

• Directionality: Consider epitope tagging approaches (e.g., FLAG-tagged MRPL51) as an alternative strategy if antibody-based IP is problematic.

• Detection methods: Use sensitive Western blotting or mass spectrometry to identify co-precipitated proteins, focusing on expected mitochondrial ribosomal partners.

• Validation: Confirm identified interactions with reciprocal co-IPs, proximity ligation assays, or other orthogonal methods.

How can researchers effectively use MRP1 antibodies in high-throughput screening for novel inhibitors or modulators?

For effectively using MRP1 antibodies in high-throughput screening for novel inhibitors or modulators, researchers should consider these methodological approaches:

• Assay format selection: Develop cell-based immunoassays in 96- or 384-well formats using validated MRP1 antibodies at optimized concentrations (e.g., 1/1000 for immunofluorescence applications) .

• Readout optimization: Implement automated fluorescence microscopy with subcellular localization analysis to detect MRP1 trafficking changes in response to compounds.

• Reporter systems: Consider developing stable cell lines expressing MRP1 fused to reporter tags (e.g., GFP) for live-cell imaging, complemented with antibody validation.

• Antibody specificity: Confirm specificity using ABCC1 knockout controls similar to those used in validation studies to ensure signal changes are MRP1-specific.

• Counter-screens: Include antibodies against related transporters (e.g., MRP2) to assess inhibitor selectivity, especially when the antibody might cross-react as seen with some MRP1 antibodies .

• Positive controls: Include known MRP1 inhibitors at various concentrations to establish assay dynamic range.

• Functional correlation: Correlate antibody-based measurements with functional assays (e.g., calcein-AM efflux) on selected hits.

• Automation compatibility: Optimize fixation, antibody incubation, and washing steps for automated liquid handling systems.

• Data analysis pipeline: Develop robust image analysis algorithms to quantify multiple parameters (intensity, localization, aggregation) from antibody staining.

• Validation cascade: Design a tiered approach moving from primary antibody-based screening to secondary functional assays for promising hits.